BR0215858A - método para descoberta de drogas - Google Patents

método para descoberta de drogas

Info

Publication number
BR0215858A
BR0215858A BRPI0215858-2A BR0215858A BR0215858A BR 0215858 A BR0215858 A BR 0215858A BR 0215858 A BR0215858 A BR 0215858A BR 0215858 A BR0215858 A BR 0215858A
Authority
BR
Brazil
Prior art keywords
drug discovery
discovery method
target
active area
assay results
Prior art date
Application number
BRPI0215858-2A
Other languages
English (en)
Inventor
Dror Ofer
Original Assignee
Keddem Bio Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keddem Bio Science Ltd filed Critical Keddem Bio Science Ltd
Publication of BR0215858A publication Critical patent/BR0215858A/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Computing Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODO PARA A DESCOBERTA DE DROGAS". Método para obter informações a respeito de uma área quimicamente ativa de uma molécula-alvo, por exemplo, para descoberta de fármacos, compreendendo: prover um conjunto de padrões químicos substancialmente rígidos; reagir o dito alvo com uma pluralidade de padrões do dito conjunto de padrões; ensaiar uma ligação dos ditos padrões com o dito alvo para obter uma pluralidade de resultados de ensaios; e analisar os ditos resultados de ensaios para obter informações a respeito da dita área quimicamente ativa.
BRPI0215858-2A 2002-07-24 2002-07-24 método para descoberta de drogas BR0215858A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2002/000614 WO2004010136A1 (en) 2002-07-24 2002-07-24 Drug discovery method

Publications (1)

Publication Number Publication Date
BR0215858A true BR0215858A (pt) 2006-06-06

Family

ID=30471435

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0215858-2A BR0215858A (pt) 2002-07-24 2002-07-24 método para descoberta de drogas
BRPI0215858-2A BRPI0215858B1 (pt) 2002-07-24 2002-07-24 método para obter informações a respeito de uma área quimicamente ativa de uma molécula-alvo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0215858-2A BRPI0215858B1 (pt) 2002-07-24 2002-07-24 método para obter informações a respeito de uma área quimicamente ativa de uma molécula-alvo

Country Status (11)

Country Link
US (3) US8019550B2 (pt)
EP (2) EP2581849A1 (pt)
JP (1) JP5166675B2 (pt)
CN (1) CN1668918A (pt)
AU (1) AU2002321793B8 (pt)
BR (2) BR0215858A (pt)
CA (1) CA2493461C (pt)
EA (1) EA010258B1 (pt)
IL (1) IL166450A0 (pt)
MX (1) MXPA05001038A (pt)
WO (1) WO2004010136A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2581849A1 (en) * 2002-07-24 2013-04-17 Keddem Bio-Science Ltd. Drug discovery method
DE102004010954A1 (de) * 2004-03-03 2005-10-06 Novaled Gmbh Verwendung eines Metallkomplexes als n-Dotand für ein organisches halbleitendes Matrixmaterial, organisches Halbleitermaterial und elektronisches Bauteil
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2452294A2 (en) * 2009-07-07 2012-05-16 The Procter & Gamble Company Property-space similarity modeling
US9218460B2 (en) * 2011-05-09 2015-12-22 The Regents Of The University Of California Defining and mining a joint pharmacophoric space through geometric features
CN102797043B (zh) * 2011-05-23 2015-11-25 天利康（天津）科技有限公司 药物分子片段库及其构建方法
US9747424B2 (en) * 2011-11-18 2017-08-29 Transparency Life Science, Llc Systems and methods for drug development
US20140180660A1 (en) * 2012-12-14 2014-06-26 Life Technologies Holdings Pte Limited Methods and systems for in silico design
EP3128451A1 (en) * 2015-08-07 2017-02-08 Molomics Biotech, S.L. Method, computer program, video game and system for optimizing a molecule for medical applications
RU2748234C2 (ru) 2016-12-23 2021-05-21 Эксофарм Лтд Способы и композиции для очистки или выделения микровезикул и экзосом
US10430395B2 (en) 2017-03-01 2019-10-01 International Business Machines Corporation Iterative widening search for designing chemical compounds
RU2743316C1 (ru) * 2020-08-14 2021-02-17 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Способ идентификации участков связывания белковых комплексов

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016712A1 (en) 1993-12-15 1995-06-22 Smithkline Beecham Corporation Compounds and methods
AU4945697A (en) 1996-10-09 1998-05-05 Novartis Ag Solid phase synthesis of heterocyclic compounds
US5846722A (en) * 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
CA2279571A1 (en) 1997-02-06 1998-08-13 Novalon Pharmaceutical Corporation Electrochemical probes for detection of molecular interactions and drug discovery
AU1925699A (en) 1997-12-18 1999-07-05 Sepracor, Inc. Methods for the simultaneous identification of novel biological targets and leadstructures for drug development
AU2887099A (en) * 1998-03-06 1999-09-20 Abbott Laboratories Ligand screening and design by x-ray crystallography
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
EP1153358A2 (en) * 1998-10-28 2001-11-14 Glaxo Group Limited Pharmacophore fingerprinting in qsar and primary library design
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
EP1203330A2 (en) * 1999-04-02 2002-05-08 Neogenesis, Inc. Analyzing molecule and protein diversity
AU745917C (en) 1999-12-08 2007-03-29 Agouron Pharmaceuticals, Inc. High-throughput screening of compounds using electrospray ionization mass spectrometry
US6143776A (en) 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
US6813615B1 (en) 2000-09-06 2004-11-02 Cellomics, Inc. Method and system for interpreting and validating experimental data with automated reasoning
WO2002042773A2 (en) 2000-11-21 2002-05-30 Sunesis Pharmaceuticals, Inc. An extended tethering approach for rapid identification of ligands
WO2002044128A2 (en) 2000-11-28 2002-06-06 Sunesis Pharmaceuticals, Inc. Salicylate analogs as interleukin-4 antagonists
JP2003133529A (ja) 2001-10-24 2003-05-09 Sony Corp 情報記憶装置およびその製造方法
EP2581849A1 (en) * 2002-07-24 2013-04-17 Keddem Bio-Science Ltd. Drug discovery method

Also Published As

Publication number Publication date
AU2002321793A1 (en) 2004-02-09
US20160314241A1 (en) 2016-10-27
EP2581849A1 (en) 2013-04-17
CA2493461A1 (en) 2004-01-29
US9405885B2 (en) 2016-08-02
EP1540329A1 (en) 2005-06-15
BRPI0215858B1 (pt) 2020-11-10
EA010258B1 (ru) 2008-06-30
JP2006507480A (ja) 2006-03-02
EA200500253A1 (ru) 2006-06-30
JP5166675B2 (ja) 2013-03-21
US20110237458A1 (en) 2011-09-29
WO2004010136A1 (en) 2004-01-29
US20050277117A1 (en) 2005-12-15
CA2493461C (en) 2013-01-08
MXPA05001038A (es) 2005-09-12
EP1540329A4 (en) 2009-06-10
US8019550B2 (en) 2011-09-13
AU2002321793B2 (en) 2009-06-18
AU2002321793B8 (en) 2009-07-09
IL166450A0 (en) 2006-01-15
CN1668918A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
BR0215858A (pt) método para descoberta de drogas
Yang et al. Pharmacological inhibition of LSD1 for cancer treatment
Biggar et al. Non-histone protein methylation as a regulator of cellular signalling and function
Dahan et al. The fraction dose absorbed, in humans, and high jejunal human permeability relationship
Hazeldine et al. Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1
Mwakwari et al. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton
Bemis et al. Discovery of oxazolo [4, 5-b] pyridines and related heterocyclic analogs as novel SIRT1 activators
Melillo et al. Synergistic effects of stereochemistry and appendages on the performance diversity of a collection of synthetic compounds
ATE432361T1 (de) Vorrichtung mit integrierter mikromatrize
WO2002057414A3 (en) Leukocyte expression profiling
Anderle et al. Changes in the transcriptional profile of transporters in the intestine along the anterior-posterior and crypt-villus axes
WO2002026195A3 (en) Oncology tissue microarrays
DE60307645D1 (de) Hoch-durchsatz assay zur messung von zellulären antworten mit hilfe von mikroarrays
WO2005067391A3 (en) Diagnostic test for parkinson's disease
JP2022508575A (ja) 測定システム
Gurard-Levin et al. The activity of HDAC8 depends on local and distal sequences of its peptide substrates
US20070020623A1 (en) Method for determining homeostasis of the skin
JP2009075116A (ja) タンパク質−タンパク質相互作用の解析および標識の方法
WO2002102229A3 (en) Diagnosing tumorigenicity and determining resistance to anticancer therapy
JP2022508576A (ja) 電極装備
EP1310567A3 (de) Nukleinsäure-Array
Musiol et al. N, N ‘-Di-tert-butoxycarbonyl-1 H-benzotriazole-1-carboxamidine Derivatives Are Highly Reactive Guanidinylating Reagents
SE0400783D0 (sv) Mönstringsmetod för biosensorapplikationer
DK1355152T3 (da) Fremgangsmåde til at identificere en forbindelse til modulering af wnt-signalkaskaden
WO2004087070A3 (en) METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-FUNGAL AGENTS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3O ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2038 DE 26/01/2010.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2680 DE 17-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.